WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Monday, November 08, 2004

Hide?	Set Name	Query	Hit Count
	DB=USPT; PLUR=YES; OP=ADJ		
☐	L15	5441931	8
☐	L14	5223409.pn.	1
☐	L13	5223409	975
☐	L12	5436153.pn.	1
☐	L11	5436153	10
	DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ		
☐	L10	L9 not l7	9
☐	L9	L8 with (disease or condition)	9
☐	L8	l5 with kallikrein	229
	DB=USPT; PLUR=YES; OP=ADJ		
☐	L7	L6 and kallikrein	6
☐	L6	L5 and l2	33
☐	L5	inhibitor with protease	12730
☐	L2	white.in.	12319
☐	L1	6613890	1

END OF SEARCH HISTORY

h e b b cg b chh e e b f c e

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 9 of 9 returned.

☐ 1. Document ID: US 5935854 A

Using default format because multiple data bases are involved.

L10: Entry 1 of 9 File: USPT Aug 10, 1999

US-PAT-NO: 5935854
DOCUMENT-IDENTIFIER: US 5935854 A

TITLE: Human amyloid protein precursor homolog and kunitz-type inhibitor

DATE-ISSUED: August 10, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Sprecher; Cindy A.	Seattle	WA		
Foster; Donald C.	Seattle	WA		
Norris; Kjeld E.	Hellerup			DK

US-CL-CURRENT: 435/331; 530/387.9, 530/388.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw De

☐ 2. Document ID: US 5677146 A

L10: Entry 2 of 9 File: USPT Oct 14, 1997

US-PAT-NO: 5677146
DOCUMENT-IDENTIFIER: US 5677146 A

TITLE: Human amyloid protein precursor homolog and kunitz-type inhibitor

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw De

☐ 3. Document ID: US 5532124 A

L10: Entry 3 of 9 File: USPT Jul 2, 1996

US-PAT-NO: 5532124
DOCUMENT-IDENTIFIER: US 5532124 A
** See image for Certificate of Correction **

TITLE: Genetically engineered bacteria to identify and produce medically important

h e b b g e e e f e ef b e

agents

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw De

4. Document ID: US 5441931 A

L10: Entry 4 of 9 File: USPT Aug 15, 1995

US-PAT-NO: 5441931
DOCUMENT-IDENTIFIER: US 5441931 A

TITLE: Human amyloid protein precursor homologue and Kunitz-type inhibitors

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw De

5. Document ID: US 5290762 A

L10: Entry 5 of 9 File: USPT Mar 1, 1994

US-PAT-NO: 5290762
DOCUMENT-IDENTIFIER: US 5290762 A

TITLE: Treatment of inflammation

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw De

6. Document ID: US 4849353 A

L10: Entry 6 of 9 File: USPT Jul 18, 1989

US-PAT-NO: 4849353
DOCUMENT-IDENTIFIER: US 4849353 A

TITLE: Immunocapture of enzyme inhibitor, enzyme complexes and uses thereof

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw De

7. Document ID: US 4518528 A

L10: Entry 7 of 9 File: USPT May 21, 1985

US-PAT-NO: 4518528
DOCUMENT-IDENTIFIER: US 4518528 A

TITLE: .alpha. Amino fluoro ketones

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw De

h e b b g e e e f e ef b e

8. Document ID: US 4118481 A

L10: Entry 8 of 9 File: USPT Oct 3, 1978

US-PAT-NO: 4118481
DOCUMENT-IDENTIFIER: US 4118481 A
** See image for Certificate of Correction **

TITLE: Deamino derivatives of the kallikrein-trypsin inhibitor

Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWMC | Draw De

9. Document ID: US 4035234 A

L10: Entry 9 of 9 File: USPT Jul 12, 1977

US-PAT-NO: 4035234
DOCUMENT-IDENTIFIER: US 4035234 A

TITLE: Process for the preparation of the kallikrein-trypsin inhibitor

Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWMC | Draw De

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Terms	Documents
L9 not L7	9

Display Format: - Change Format

Previous Page Next Page Go to Doc#

h e b b g e e e f e ef b e

```
$%^STN;HighlightOn=  ***;HighlightOff=***  ;

Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:SSSPTA1800EXS

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  JUL 12   BEILSTEIN enhanced with new display and select options,
                   resulting in a closer connection to BABS
 NEWS  4  AUG 02   IFIPAT/IFIUDB/IFICDB reloaded with new search and display
                   fields
 NEWS  5  AUG 02   CAplus and CA patent records enhanced with European and Japan
                   Patent Office Classifications
 NEWS  6  AUG 02   The Analysis Edition of STN Express with Discover!
                   (Version 7.01 for Windows) now available
 NEWS  7  AUG 27   BIOCOMMERCE: Changes and enhancements to content coverage
 NEWS  8  AUG 27   BIOTECHABS/BIOTECHDS: Two new display fields added for legal
                   status data from INPADOC
 NEWS  9  SEP 01   INPADOC: New family current-awareness alert (SDI) available
 NEWS 10  SEP 01   New pricing for the Save Answers for SciFinder Wizard within
                   STN Express with Discover!
 NEWS 11  SEP 01   New display format, HITSTR, available in WPIDS/WPINDEX/WPIX
 NEWS 12  SEP 27   STANDARDS will no longer be available on STN
 NEWS 13  SEP 27   SWETSCAN will no longer be available on STN
 NEWS 14  OCT 28   KOREAPAT now available on STN

 NEWS EXPRESS  OCTOBER 29 CURRENT WINDOWS VERSION IS V7.01A, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 18:42:58 ON 08 NOV 2004

=> fil .eliz
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'MEDLINE' ENTERED AT 18:43:10 ON 08 NOV 2004

FILE 'SCISEARCH' ENTERED AT 18:43:10 ON 08 NOV 2004
Copyright (c) 2004 The Thomson Corporation.

FILE 'LIFESCI' ENTERED AT 18:43:10 ON 08 NOV 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'BIOTECHDS' ENTERED AT 18:43:10 ON 08 NOV 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION
```

```
FILE 'BIOSIS' ENTERED AT 18:43:10 ON 08 NOV 2004
Copyright (c) 2004 The Thomson Corporation.

FILE 'EMBASE' ENTERED AT 18:43:10 ON 08 NOV 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'HCAPLUS' ENTERED AT 18:43:10 ON 08 NOV 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'NTIS' ENTERED AT 18:43:10 ON 08 NOV 2004
Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.
All rights reserved. (2004)

FILE 'ESBIOBASE' ENTERED AT 18:43:10 ON 08 NOV 2004
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'BIOTECHNO' ENTERED AT 18:43:10 ON 08 NOV 2004
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'WPIDS' ENTERED AT 18:43:10 ON 08 NOV 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

=> s protease (5a) inhibitor
L1      139452 PROTEASE (5A) INHIBITOR

=> s l1 (5a) (muta? or variant)
  10 FILES SEARCHED...
L2        2479 L1 (5A) (MUTA? OR VARIANT)

=> s l2 and kallikrein
L3          25 L2 AND KALLIKREIN

=> dup rem l3
PROCESSING COMPLETED FOR L3
L4           20 DUP REM L3 (5 DUPLICATES REMOVED)

=> s l2 and plasmin
L5          31 L2 AND PLASMIN

=> s l2 and factor xii?
L6          18 L2 AND FACTOR XII?

=> s l5 not l3
L7          20 L5 NOT L3

=> s l6 not l3
L8           8 L6 NOT L3

=> s l3 and l5 and l6
L9           2 L3 AND L5 AND L6

=> dup rem l9
PROCESSING COMPLETED FOR L9
L10           2 DUP REM L9 (0 DUPLICATES REMOVED)

=> d 1,2

L10  ANSWER 1 OF 2  HCAPLUS  COPYRIGHT 2004 ACS on STN
AN   1994:242123  HCAPLUS
DN   120:242123
TI   The balance between inhibition and substrate-type reactions of recombinant
     C1 inhibitor P5/P3 variants
AU   Eldering, E.; Huijbregts, C. C. M.; Nuijens, J. H.; Hack, C. E.
CS   Cent. Lab. Netherlands Red Cross Blood Transfus. Serv., Univ. Amsterdam,
     Amsterdam, Neth.
SO   Behring Institute Mitteilungen (1993), 93(Structure-Function-Relationship
     of C1q and Collectins C1-Esterases:  C1r, C1s and C1-Inhibitor in Health
     and Disease), 125-30
     CODEN: BHIMA2; ISSN: 0301-0457
DT   Journal
LA   English

L10  ANSWER 2 OF 2  HCAPLUS  COPYRIGHT 2004 ACS on STN
```

AN 1991:576699 HCAPLUS
DN 115:176699
TI Recombinant preparation of serpin-resistant serine proteinases of the chymotrypsin superfamily
IN Sambrook, Joseph F.; Madison, Edwin L.; Goldsmith, Elizabeth J.; Gething, Maryjane H.; Gerard, Robert D.
PA University of Texas System, USA
SO PCT Int. Appl., 76 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9010649	A1	19900920	WO 1990-US947	19900301
	W: AU, BB, BG, BR, CA, FI, HU, JP, KP, KR, LK, MC, MG, MW, NO, RO, SD, SU				
	RW: AT, BE, BF, BJ, CF, CG, CH, CM, DE, DK, ES, FR, GA, GB, IT, LU, ML, MR, NL, SE, SN, TD, TG				
	US 5550042	A	19960827	US 1989-434748	19891113
	AU 9052780	A1	19901009	AU 1990-52780	19900301
	AU 637791	B2	19930610		
	EP 462207	A1	19911227	EP 1990-905081	19900301
	EP 462207	B1	20010207		
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
	JP 04504952	T2	19920903	JP 1990-505024	19900301
	JP 2991769	B2	19991220		
	AT 199090	E	20010215	AT 1990-905081	19900301
PRAI	US 1989-319212	A	19890306		
	US 1989-434748	A	19891113		
	WO 1990-US947	A	19900301		

=> s l7 not l10
L11 20 L7 NOT L10

=> s l4 not l10
L12 18 L4 NOT L10

=> d 1-10

L12 ANSWER 1 OF 18 MEDLINE on STN
AN 86112554 MEDLINE
DN PubMed ID: 3484755
TI Alpha-1-antitrypsin-Pittsburgh. A potent inhibitor of human plasma factor XIa, ***kallikrein*** , and factor XIIf.
AU Scott C F; Carrell R W; Glaser C B; Kueppers F; Lewis J H; Colman R W
NC HL24365 (NHLBI)
SO Journal of clinical investigation, (1986 Feb) 77 (2) 631-4.
Journal code: 7802877. ISSN: 0021-9738.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 198603
ED Entered STN: 19900321
Last Updated on STN: 20000303
Entered Medline: 19860326

L12 ANSWER 2 OF 18 BIOTECHDS COPYRIGHT 2004 THE THOMSON CORP. on STN
AN 1994-03130 BIOTECHDS
TI Recombinant Kunitz-type-protease-inhibitor derivative production by vector plasmid pKol100 series expression in e.g. Saccharomyces cerevisiae;
application in e.g. emphysema, acute respiratory distress syndrome and as a vulnerary
PA Bayer
PI US 5278285 11 Jan 1994
AI US 1990-473295 1 Feb 1990
PRAI US 1990-473295 1 Feb 1990
DT Patent
LA English
OS WPI: 1994-025477 [03]

L12 ANSWER 3 OF 18 BIOTECHDS COPYRIGHT 2004 THE THOMSON CORP. on STN
AN 1991-02665 BIOTECHDS

TI ***Protease*** - ***inhibitor*** ***variant*** derived from human bikunin;
gene cloning and mutagenesis; protein engineering for improved activity; DNA sequence
PA Bayer
PI EP 401508 12 Dec 1990
AI EP 1990-108284 1 May 1990
PRAI DE 1990-1244 18 Jan 1990; DE 1989-915689 13 May 1989
DT Patent
LA German
OS WPI: 1990-369615 [50]

L12 ANSWER 4 OF 18 BIOTECHDS COPYRIGHT 2004 THE THOMSON CORP. on STN
AN 1987-06270 BIOTECHDS
TI Engineered alpha-1-antitrypsin variants of increased stability and altered specificity;
protein engineering; anticoagulant development (conference paper)
AU Courtney M
CS Transgene
LO (Pub. Address) Online Publications, Online Conferences Ltd., Pinner Green House, Ash Hill Drive, Pinner, Middlesex, HA5 2AE, U.K.
SO World Biotech Rep.; (1986) 1, B21-B26
DT Journal
LA English

L12 ANSWER 5 OF 18 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:746670 HCAPLUS
TI Expression, purification, biochemical and pharmacological characterization of a recombinant aprotinin variant
AU Apeler, Heiner; Peters, Joerg; Schroeder, Werner; Schneider, Karl-Heinz; Lemm, Georg; Hinz, Volker; Rossouw, Gawie J.; Dembowsky, Klaus
CS Pharma, Bayer HealthCare AG, Wuppertal, Germany
SO Arzneimittel Forschung (2004), 54(8), 483-497
CODEN: ARZNAD; ISSN: 0004-4172
PB Editio Cantor Verlag
DT Journal
LA English
RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 6 OF 18 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:927457 HCAPLUS
DN 138:21344
TI Cloning, sequence and therapeutic use of human wild-type and ***mutant*** Kunitz-type ***protease*** ***inhibitor*** HKI-18
IN Jorgensen, Marianne Ulrich; Bang, Susanne; Olsen, Ole Hvilsted; Petersen, Lars Christian
PA Novo Nordisk A/S, Den.
SO PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002096938	A2	20021205	WO 2002-DK372	20020531
	WO 2002096938	A3	20040318		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004152633	A1	20040805	US 2003-721961	20031125
PRAI	DK 2001-859	A	20010531		
	US 2001-303180P	P	20010705		
	WO 2002-DK372	A	20020531		

L12 ANSWER 7 OF 18 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:674101 HCAPLUS
DN 137:348285
TI .alpha.1-Proteinase inhibitor mutants with specificity for plasma

kallikrein and C1s but not C1
AU Sulikowski, Thomas; Bauer, Bryan A.; Patston, Philip A.
CS Department of Oral Medicine and Diagnostic Sciences, University of Illinois at Chicago, Chicago, IL, 60612, USA
SO Protein Science (2002), 11(9), 2230-2236
CODEN: PRCIEI; ISSN: 0961-8368
PB Cold Spring Harbor Laboratory Press
DT Journal
LA English
RE.CNT 61 THERE ARE 61 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 8 OF 18 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:429205 HCAPLUS
DN 137:15809
TI Adhesion protein, ***protease*** , and ***protease*** ***inhibitor*** ***mutations*** and methods for diagnosis and treatment of epithelial cell adhesion-associated diseases
IN Tazi-Ahnini, Rachid; Bavik, Claes; Ward, Simon; Duff, Gordon; Cork, Michael
PA Molecular Skincare Limited, UK
SO PCT Int. Appl., 257 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002044736	A2	20020606	WO 2001-GB5303	20011130
WO 2002044736	A3	20030828		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002020855	A5	20020611	AU 2002-20855	20011130
EP 1356298	A2	20031029	EP 2001-998835	20011130
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004524010	T2	20040812	JP 2002-546227	20011130
US 2004106120	A1	20040603	US 2003-433234	20031105
PRAI GB 2000-29225	A	20001130		
GB 2000-29879	A	20001207		
WO 2001-GB5303	W	20011130		

L12 ANSWER 9 OF 18 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:798721 HCAPLUS
DN 130:151492
TI Inhibition of serine proteases by reactive site mutants of protein C inhibitor (plasminogen activator inhibitor-3)
AU Elisen, M. G. L. M.; Bouma, B. N.; Church, F. C.; Meijers, J. C. M.
CS Department of Haematology, University Hospital, Utrecht, 3508 GA, Neth.
SO Fibrinolysis & Proteolysis (1998), 12(5), 283-291
CODEN: FBPRFP; ISSN: 1369-0191
PB Churchill Livingstone
DT Journal
LA English
RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 10 OF 18 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1997:448963 HCAPLUS
DN 127:189430
TI Role of the P2 residue of complement 1 inhibitor (Ala443) in determination of target protease specificity: Inhibition of complement and contact system proteases
AU Zahedi, Rana; Wisnieski, Jeffrey; Davis, Alvin E., III
CS Division of Nephrology, Children's Hospital Research Foundation, and Dep. of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, 45229, USA
SO Journal of Immunology (1997), 159(2), 983-988

CODEN: JOIMA3; ISSN: 0022-1767
PB American Association of Immunologists
DT Journal
LA English
RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 2,3 ab

L12 ANSWER 2 OF 18 BIOTECHDS COPYRIGHT 2004 THE THOMSON CORP. on STN
AB A modified Kunitz ***protease*** - ***inhibitor*** ***variant*** is claimed which consists of a specified protein sequence and which is modified at position 16, 17 and 39 by Ala16, Arg17 and Arg39. In a wider disclosure a new Kunitz-type protease-inhibitor is disclosed whose protein sequence was deduced from cDNA clones which cover 3 kb of the type IV collagen alpha-3 chain mRNA. The cDNA was isolated from a placenta and a fibroblast cDNA bank. Also disclosed are inhibitor variants which have amino acid replacements in 1 or more positions in and/or around the active center of and optionally extensions and/or deletions. A synthetic DNA sequence of the natural alpha-3 (VI) inhibitor gene was derived from a human type IV collagen cDNA clone encoding a 58 residue part of the C-terminal globular domain C5. Site-directed mutagenesis was carried out to produce ***variants*** . The ***protease*** - ***inhibitor*** ***variant*** is a specific ***inhibitor*** of serine ***proteases*** such as plasma ***kallikrein*** (EC-3.4.21.8) and pancreatic and leukocyte elastase (EC-3.4.21.11). It can be used in the treatment of e.g. emphysema, acute respiratory distress syndrome and coagulation disorders. (9pp)

L12 ANSWER 3 OF 18 BIOTECHDS COPYRIGHT 2004 THE THOMSON CORP. on STN
AB New protease-inhibitors (I) comprise protein sequence 21-147 of human bikunin in which at least 1 amino acid has been exchanged for another, and may have an additional N-terminal peptide containing amino acids 1-21 of human bikunin. Also new are fragments of (I), preferably fragments of sequences 22-77, 1-77 and 78-147, having protease-inhibitor activity. Preferred compounds have the following alterations, in any suitable combination: Met-36 replaced by Leu, Ile, Val, Arg, Phe, Tyr, Trp or Lys; Met-38 by Leu, Arg, Ile, Val or Lys; Asn-45 by another amino acid; Arg-92 by Leu, Ile, Val, Phe or Lys; Phe-94 by Leu, Arg, Lys, Ile or Val; Trp-98 by Lys, Ile, Val, Phe, Leu, Ala, Gly or Ser; and/or Glu-116 by Arg or Lys. (I) may be glycosylated or nonglycosylated. The protein engineering is performed using synthetic genes cloned into vector plasmids and expressed in bacterial or eukaryotic cells, or by mutagenesis of the natural gene. The products have elastase-inhibitor, cathepsin-G-inhibitor and ***kallikrein*** -inhibitor activity. They may be used in therapy of emphysema, septic shock, rheumatoid arthritis, coagulation disorders, etc. (29pp)

=> d 11-18

L12 ANSWER 11 OF 18 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1996:538912 HCAPLUS
DN 125:239601
TI Selection for protease inhibitors using bacteriophage display
AU Markland, William; Roberts, Bruce L.; Ladner, Robert C.
CS Vertex Pharm., Inc., Cambridge, MA, 02139, USA
SO Methods in Enzymology (1996), 267(Combinatorial Chemistry), 28-51
CODEN: MENZAU; ISSN: 0076-6879
PB Academic
DT Journal
LA English

L12 ANSWER 12 OF 18 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1993:55124 HCAPLUS
DN 118:55124
TI Proteinase inhibitors derived from the protease-inhibiting region of amyloid precursor protein
IN Kitaguchi, Nobuya; Shiojiri, Satoshi; Takahashi, Yasuyuki
PA Asahi Chemical Industry Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 17 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 04166087	A2	19920611	JP 1990-287074	19901026
PRAI	JP 1990-287074		19901026		

L12 ANSWER 13 OF 18 WPIDS COPYRIGHT 2004 THE THOMSON CORP on STN
AN 2004-719232 [70] WPIDS
DNC C2004-253472
TI New chimeric inhibitor protein of a protease comprises an inhibiting polypeptide sequence and a polypeptide sequence of a substrate-enzyme interaction site specific for the protease, useful for treating or preventing, e.g. cancer.
DC B04 D16
IN CLOUTIER, S; DEPERTHES, D
PA (UYLA-N) UNIV LAUSANNE
CYC 108
PI WO 2004087912 A1 20041014 (200470)* EN 65 C12N015-09
RW: AT BE BG BW CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS LU MC MW MZ NL OA PL PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
ADT WO 2004087912 A1 WO 2004-IB1040 20040405
PRAI US 2003-460345P 20030404
IC ICM C12N015-09
ICS A61K037-64; C12N009-64; C12N015-15; C12P021-02

L12 ANSWER 14 OF 18 WPIDS COPYRIGHT 2004 THE THOMSON CORP on STN
AN 1993-243151 [30] WPIDS
DNC C1993-108373
TI New human Kunitz-type ***protease*** ***inhibitor*** and ***variants*** - are for treating pathological proteolysis, e.g. pancreatitis, inflammation or thrombocytopenia, and derived DNA, vectors and host cells.
DC B04 D16
IN BJORN, S E; FOSTER, D C; NORRIS, F; NORRIS, K; OLSEN, O; PETERSEN, L C; SPRECHER, C A; FOSTER, D; PETERSEN, L; BJOERN, S E; OLSEN, O H
PA (NOVO) NOVO-NORDISK AS
CYC 31

PI	WO 9314123	A1 19930722 (199330)* EN	38	C07K007-10	
	RW: AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE				
	W: AU CA CZ FI HU JP KR NO NZ PL RU SK US				
	AU 9333461	A 19930803 (199348)		C07K007-10	
	ZA 9300094	A 19931027 (199349)	40	A61K000-00	
	FI 9403235	A 19940706 (199435)		C07K000-00	
	NO 9402553	A 19940907 (199439)		C07K007-10	
	EP 621873	A1 19941102 (199442) EN		C07K007-10	
	R: AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE				
	CZ 9401648	A3 19941215 (199508)		C07K007-10	
	JP 07504652	W 19950525 (199529)		C07K014-81	
	HU 70291	T 19950928 (199546)		C07K014-00	
	AU 670059	B 19960704 (199634)		C07K007-10	
	NZ 246571	A 19960925 (199644)		C12N015-15	
	US 5618696	A 19970408 (199720)	23	C12N015-00	
	EP 621873	B1 19980930 (199843) EN		C07K014-81	
	R: AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE				
	DE 69321342	E 19981105 (199850)		C07K014-81	
	ES 2123635	T3 19990116 (199909)		C07K014-81	
	JP 3345420	B2 20021118 (200279)	17	C07K014-81	

ADT WO 9314123 A1 WO 1993-DK6 19930107; AU 9333461 A AU 1993-33461 19930107, WO 1993-DK6 19930107; ZA 9300094 A ZA 1993-94 19930107; FI 9403235 A WO 1993-DK6 19930107, FI 1994-3235 19940706; NO 9402553 A WO 1993-DK6 19930107, NO 1994-2553 19940706; EP 621873 A1 EP 1993-902107 19930107, WO 1993-DK6 19930107; CZ 9401648 A3 CZ 1994-1648 19930107; JP 07504652 W JP 1993-512084 19930107, WO 1993-DK6 19930107; HU 70291 T WO 1993-DK6 19930107, HU 1994-1989 19930107; AU 670059 B AU 1993-33461 19930107; NZ 246571 A NZ 1993-246571 19930107, WO 1993-DK6 19930107; US 5618696 A Cont of WO 1993-DK6 19930107, Cont of US 1993-21534 19930222, US 1995-384489 19950206; EP 621873 B1 EP 1993-902107 19930107, WO 1993-DK6 19930107; DE 69321342 E DE 1993-621342 19930107, EP 1993-902107 19930107, WO 1993-DK6 19930107; ES 2123635 T3 EP 1993-902107 19930107; JP 3345420 B2 JP 1993-512084 19930107, WO 1993-DK6 19930107
FDT AU 9333461 A Based on WO 9314123; EP 621873 A1 Based on WO 9314123; JP 07504652 W Based on WO 9314123; HU 70291 T Based on WO 9314123; AU 670059

B Previous Publ. AU 9333461, Based on WO 9314123; NZ 246571 A Based on WO 9314123; EP 621873 B1 Based on WO 9314123; DE 69321342 E Based on EP 621873, Based on WO 9314123; ES 2123635 T3 Based on EP 621873; JP 3345420 B2 Previous Publ. JP 07504652, Based on WO 9314123
PRAI WO 1992-DK3 19920107
IC ICM A61K000-00; C07K007-10; C07K014-00; C07K014-81; C12N015-00; C12N015-15
ICS A01N000-00; A61K037-64; A61K038-55; C12N001-19; C12N005-10; C12N009-99; C12N015-09; C12N015-12; C12P021-00; C12P021-02
ICI C12P021-02, C12R001:865

L12 ANSWER 15 OF 18 WPIDS COPYRIGHT 2004 THE THOMSON CORP on STN
AN 1993-243150 [30] WPIDS
CR 1993-243147 [30]
DNC C1993-108372
TI New ***variants*** of human Kunitz ***protease*** ***inhibitor*** domain 1 - of tissue factor pathway inhibitor, with selective activity, for treating proteolytic diseases, e.g. pancreatitis or inflammation.
DC B04 D16
IN BJORN, S E; NORRIS, F; NORRIS, K; OLSEN, O H; PETERSEN, L C; OLSEN, O; BJORN, S; PETERSEN, L; BJOERN, S E; PETERSON, L C
PA (NOVO) NOVO-NORDISK AS
CYC 31
PI WO 9314122 A1 19930722 (199330)* EN 35 C07K007-10
RW: AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
W: AU CA CZ FI HU JP KR NO NZ PL RU SK US
AU 9333460 A 19930803 (199348) C07K007-10
ZA 9300096 A 19931027 (199349) 54 A61K000-00
FI 9403234 A 19940706 (199435) C07K000-00
NO 9402549 A 19940907 (199439) C07K007-10
EP 621872 A1 19941102 (199442) EN C07K007-10
R: AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE
CZ 9401644 A3 19941215 (199508) C07K007-10
JP 07504891 W 19950601 (199530) C07K014-81
HU 70293 T 19950928 (199546) C07K014-10
NZ 246570 A 19960925 (199644) C12N015-15
AU 675926 B 19970227 (199717) C07K007-10
ADT WO 9314122 A1 WO 1993-DK5 19930107; AU 9333460 A AU 1993-33460 19930107, WO 1993-DK5 19930107; ZA 9300096 A ZA 1993-96 19930107; FI 9403234 A WO 1993-DK5 19930107, FI 1994-3234 19940706; NO 9402549 A WO 1993-DK5 19930107, NO 1994-2549 19940706; EP 621872 A1 EP 1993-902106 19930107, WO 1993-DK5 19930107; CZ 9401644 A3 CZ 1994-1644 19930107; JP 07504891 W JP 1993-511993 19930107, WO 1993-DK5 19930107; HU 70293 T WO 1993-DK5 19930107, HU 1994-1990 19930107; NZ 246570 A NZ 1993-246570 19930107, WO 1993-DK5 19930107; AU 675926 B AU 1993-33460 19930107
FDT AU 9333460 A Based on WO 9314122; EP 621872 A1 Based on WO 9314122; JP 07504891 W Based on WO 9314122; HU 70293 T Based on WO 9314122; NZ 246570 A Based on WO 9314122; AU 675926 B Previous Publ. AU 9333460, Based on WO 9314122
PRAI WO 1992-DK340 19921116; WO 1992-DK2 19920107
IC ICM A61K000-00; C07K000-00; C07K007-10; C07K014-10; C07K014-81; C12N015-15
ICS A01N000-00; A61K037-64; A61K038-55; C12N001-19; C12N005-10; C12P021-00

L12 ANSWER 16 OF 18 WPIDS COPYRIGHT 2004 THE THOMSON CORP on STN
AN 1993-243149 [30] WPIDS
DNC C1993-108371
TI New ***variants*** of human Kunitz ***protease*** ***inhibitor*** domain 2 - of tissue factor pathway inhibitor, with selective activity, for treating proteolytic diseases, e.g. pancreatitis or inflammation.
DC B04 D16
IN BJORN, S E; NORRIS, F; NORRIS, K; OLSEN, O H; PETERSEN, L C; OLSEN, O; BJRN, S E; PETERSEN, L; BJ RN, S E; BJOERN, S E
PA (NOVO) NOVO-NORDISK AS; (NOVO) NOVO NORDISK AS
CYC 32
PI WO 9314121 A1 19930722 (199330)* EN 54 C07K007-10
RW: AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
W: AU CA CZ FI HU JP KR NO NZ PL RU SK US
AU 9333459 A 19930803 (199348) C07K007-10
ZA 9300095 A 19931027 (199349) 24 A61K000-00
FI 9403233 A 19940706 (199435) C07K000-00
NO 9402550 A 19940907 (199439) C07K007-10
EP 621871 A1 19941102 (199442) EN C07K007-10

```
        R: AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE
      CZ 9401649       A3 19941215 (199508)                C07K007-10
      JP 07506335      W  19950713 (199536)        19      C07K014-47
      HU 70295         T  19950928 (199546)                C07K014-00
      NZ 246569        A  19960528 (199626)                C07K014-81
      US 5576294       A  19961119 (199701)        23      A61K038-00
      AU 676145        B  19970306 (199718)                C07K007-10
      EP 621871        B1 19970702 (199731)  EN    42      C07K014-81
        R: AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE
      DE 69311893      E  19970807 (199737)                C07K014-81
      ES 2104121       T3 19971001 (199746)                C07K014-81
      CZ 284911        B6 19990414 (199921)                C07K014-81
      HU 218104        B  20000628 (200039)                C07K014-00
      IL 104325        A  20001031 (200059)                C07K014-81
      KR 278036        B  20010115 (200208)                C07K014-00
      JP 3350549       B2 20021125 (200301)        32      C07K014-81
ADT   WO 9314121 A1 WO 1993-DK4 19930107; AU 9333459 A AU 1993-33459 19930107,
      WO 1993-DK4 19930107; ZA 9300095 A ZA 1993-95 19930107; FI 9403233 A WO
      1993-DK4 19930107, FI 1994-3233 19940706; NO 9402550 A WO 1993-DK4
      19930107, NO 1994-2550 19940706; EP 621871 A1 EP 1993-902105 19930107, WO
      1993-DK4 19930107; CZ 9401649 A3 CZ 1994-1649 19930107; JP 07506335 W JP
      1993-511992 19930107, WO 1993-DK4 19930107; HU 70295 T WO 1993-DK4
      19930107, HU 1994-1991 19930107; NZ 246569 A NZ 1993-246569 19930107, WO
      1993-DK4 19930107; US 5576294 A Cont of WO 1993-DK4 19930107, Cont of US
      1993-21610 19930222, US 1994-321658 19941012; AU 676145 B AU 1993-33459
      19930107; EP 621871 B1 EP 1993-902105 19930107, WO 1993-DK4 19930107; DE
      69311893 E DE 1993-611893 19930107, EP 1993-902105 19930107, WO 1993-DK4
      19930107; ES 2104121 T3 EP 1993-902105 19930107; CZ 284911 B6 WO 1993-DK4
      19930107, CZ 1994-1649 19930107; HU 218104 B WO 1993-DK4 19930107, HU
      1994-1991 19930107; IL 104325 A IL 1993-104325 19930106; KR 278036 B WO
      1993-DK4 19930107, KR 1994-702351 19940707; JP 3350549 B2 JP 1993-511992
      19930107, WO 1993-DK4 19930107
FDT   AU 9333459 A Based on WO 9314121; EP 621871 A1 Based on WO 9314121; JP
      07506335 W Based on WO 9314121; HU 70295 T Based on WO 9314121; NZ 246569
      A Based on WO 9314121; AU 676145 B Previous Publ. AU 9333459, Based on WO
      9314121; EP 621871 B1 Based on WO 9314121; DE 69311893 E Based on EP
      621871, Based on WO 9314121; ES 2104121 T3 Based on EP 621871; CZ 284911
      B6 Previous Publ. CZ 9401649, Based on WO 9314121; HU 218104 B Previous
      Publ. HU 70295, Based on WO 9314121; KR 278036 B Previous Publ. KR
      94703854, Based on WO 9314121; JP 3350549 B2 Previous Publ. JP 07506335,
      Based on WO 9314121
PRAI  WO 1992-DK1          19920107
IC    ICM  A61K000-00; A61K038-00; C07K000-00; C07K007-10; C07K014-00;
           C07K014-47; C07K014-81
      ICS  A01N000-00; A61K037-64; A61K038-55; A61K038-57; A61P001-18;
           A61P007-00; A61P011-00; A61P029-00; C07H019-00; C07K001-00;
           C12N009-99; C12N015-09; C12N015-15; C12N015-63; C12P021-02;
           C12P021-06
ICI   C12P021-02, C12R001:865

L12   ANSWER 17 OF 18  WPIDS  COPYRIGHT 2004 THE THOMSON CORP on STN
AN    1993-243148 [30]   WPIDS
DNC   C1993-108370
TI    New   ***variants***   of human Kunitz   ***protease***
        ***inhibitor***   domains - of tissue factor pathway inhibitor, with
      selective activity, for treating proteolytic disease, e.g. pancreatitis or
      inflammation.
DC    B04 D16
IN    BJORN, S E; NORRIS, F; NORRIS, K; OLSEN, O H; PETERSEN, L C; OLSEN, O;
      BOJRN, S E; PETERSEN, L; BJOERN, S E
PA    (NOVO) NOVO-NORDISK AS
CYC   31
PI    WO 9314120       A1 19930722 (199330)* EN    21      C07K007-10
         RW: AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
          W: AU CA CZ FI HU JP KR NO NZ PL RU SK US
      AU 9333458       A  19930803 (199348)                C07K007-10
      ZA 9300097       A  19931027 (199349)        34      A61K000-00
      FI 9403232       A  19940706 (199435)                C07K000-00
      NO 9402551       A  19940907 (199439)                C07K007-10
      EP 621870        A1 19941102 (199442)  EN            C07K007-10
        R: AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE
      CZ 9401645       A3 19941215 (199508)                C07K007-10
      JP 07506241      W  19950713 (199536)         8      C12N015-09
      HU 70294         T  19950928 (199546)                C07K014-00
      NZ 246568        A  19960227 (199614)                C07K014-81
      AU 675925        B  19970227 (199717)                C07K007-10
```

```
      EP 621870       B1 19970507 (199723)  EN   14    C07K014-81
          R: AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE
      DE 69310499     E  19970612 (199729)             C07K014-81
ADT   WO 9314120 A1 WO 1993-DK3 19930107; AU 9333458 A AU 1993-33458 19930107,
      WO 1993-DK3 19930107; ZA 9300097 A ZA 1993-97 19930107; FI 9403232 A WO
      1993-DK3 19930107, FI 1994-3232 19940706; NO 9402551 A WO 1993-DK3
      19930107, NO 1994-2551 19940706; EP 621870 A1 EP 1993-902104 19930107, WO
      1993-DK3 19930107; CZ 9401645 A3 CZ 1994-1645 19930107; JP 07506241 W JP
      1993-511991 19930107, WO 1993-DK3 19930107; HU 70294 T WO 1993-DK3
      19930107, HU 1994-1992 19930107; NZ 246568 A NZ 1993-246568 19930107; AU
      675925 B AU 1993-33458 19930107; EP 621870 B1 EP 1993-902104 19930107, WO
      1993-DK3 19930107; DE 69310499 E DE 1993-610499 19930107, EP 1993-902104
      19930107, WO 1993-DK3 19930107
FDT   AU 9333458 A Based on WO 9314120; EP 621870 A1 Based on WO 9314120; JP
      07506241 W Based on WO 9314120; HU 70294 T Based on WO 9314120; AU 675925
      B Previous Publ. AU 9333458, Based on WO 9314120; EP 621870 B1 Based on WO
      9314120; DE 69310499 E Based on EP 621870, Based on WO 9314120
PRAI  WO 1992-DK4          19920107
IC    ICM  A61K000-00; C07K000-00; C07K007-10; C07K014-00; C07K014-81;
           C12N015-09
      ICS  A01N000-00; A61K037-64; A61K038-55; A61K038-57; C12N005-10;
           C12N015-15; C12N015-63; C12P021-00

L12   ANSWER 18 OF 18  WPIDS  COPYRIGHT 2004 THE THOMSON CORP on STN
AN    1993-243147 [30]   WPIDS
CR    1993-243150 [30]
DNC   C1993-108369
TI    Human Kunitz-type   ***protease***     ***inhibitor***     ***variants***
      - for treating and preventing diseases associated with pathological
      proteolysis e.g. acute pancreatitis, inflammation, thrombocytopaenia etc..
DC    B04 D16
IN    BJORN, S E; NORRIS, F; NORRIS, K; OLSEN, O H; PETERSEN, L C; OLSEN, O;
      BJOERN, SOEREN E; BJOERN, S; PETERSEN, L; BJOERN, S E
PA    (NOVO) NOVO-NORDISK AS
CYC   31
PI    WO 9314119      A1 19930722 (199330)* EN   33    C07K007-10
         RW: AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
          W: AU CA CZ FI HU JP KR NO NZ PL RU SK US
      AU 9333457      A  19930803 (199348)             C07K007-10
      ZA 9300098      A  19931027 (199349)        33   A61K000-00
      FI 9403231      A  19940706 (199435)             C07K000-00
      NO 9402552      A  19940907 (199439)             C07K007-10
      EP 621869       A1 19941102 (199442)  EN         C07K007-10
          R: AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE
      CZ 9401646      A3 19941215 (199508)             C07K007-10
      JP 07506334     W  19950713 (199536)        11   C07K014-47
      HU 70292        T  19950928 (199546)             C07K014-00
      NZ 246567       A  19960528 (199626)             C07K014-81
      AU 671611       B  19960905 (199647)             C07K007-10
      EP 621869       B1 19970423 (199721)  EN   20    C07K014-81
          R: AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE
      US 5629176      A  19970513 (199725)        12   C12P021-06
      DE 69310141     E  19970528 (199727)             C07K014-81
ADT   WO 9314119 A1 WO 1993-DK2 19930107; AU 9333457 A AU 1993-33457 19930107,
      WO 1993-DK2 19930107; ZA 9300098 A ZA 1993-98 19930107; FI 9403231 A WO
      1993-DK2 19930107, FI 1994-3231 19940706; NO 9402552 A WO 1993-DK2
      19930107, NO 1994-2552 19940706; EP 621869 A1 EP 1993-902103 19930107, WO
      1993-DK2 19930107; CZ 9401646 A3 CZ 1994-1646 19930107; JP 07506334 W JP
      1993-511990 19930107, WO 1993-DK2 19930107; HU 70292 T WO 1993-DK2
      19930107, HU 1994-1993 19930107; NZ 246567 A NZ 1993-246567 19930107, WO
      1993-DK2 19930107; AU 671611 B AU 1993-33457 19930107; EP 621869 B1 EP
      1993-902103 19930107, WO 1993-DK2 19930107; US 5629176 A Cont of WO
      1993-DK2 19930107, Cont of US 1993-26135 19930224, US 1994-334773
      19941104; DE 69310141 E DE 1993-610141 19930107, EP 1993-902103 19930107,
      WO 1993-DK2 19930107
FDT   AU 9333457 A Based on WO 9314119; EP 621869 A1 Based on WO 9314119; JP
      07506334 W Based on WO 9314119; HU 70292 T Based on WO 9314119; NZ 246567
      A Based on WO 9314119; AU 671611 B Previous Publ. AU 9333457, Based on WO
      9314119; EP 621869 B1 Based on WO 9314119; DE 69310141 E Based on EP
      621869, Based on WO 9314119
PRAI  WO 1992-DK5          19920107; WO 1992-DK2          19920107
IC    ICM  A61K000-00; C07K000-00; C07K007-10; C07K014-00; C07K014-47;
           C07K014-81; C12P021-06
      ICS  A01N000-00; A61K037-64; A61K038-00; A61K038-55; A61K038-57;
           C07K001-00; C12N001-20; C12N015-15
```

=> d 13 ab

L12 ANSWER 13 OF 18 WPIDS COPYRIGHT 2004 THE THOMSON CORP on STN
AB WO2004087912 A UPAB: 20041101
NOVELTY - A chimeric inhibitor protein of a protease (I) comprises an inhibiting polypeptide sequence and at least one polypeptide sequence of a substrate-enzyme interaction site specific for the protease, is new.
DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:
(1) a purified and isolated DNA sequence encoding (I);
(2) an expression vector comprising the purified and isolated DNA sequence of (1);
(3) a eukaryotic or prokaryotic host cell transfected with the expression vector of (2);
(4) a pharmaceutical composition comprising (I) as an active agent, and optionally in combination with one or more pharmaceutical carriers;
(5) treating or preventing a proteolysis-associated disorder in a mammal;
(6) producing the chimeric inhibitor protein of a protease; and
(7) a diagnostic kit for the detection of a protease in a specimen comprising: (a) a purified and isolated DNA sequence selected from 7 sequences comprising 1239 bp fully defined in the specification (SEQ ID NO. 1-13, odd numbers only), complementary sequences, fragments, and/or ***variants*** ; or (b) a chimeric ***inhibitor*** of a ***protease*** .
ACTIVITY - Cytostatic; Immunosuppressive; Antiinflammatory; Antimicrobial. No biological data given.
MECHANISM OF ACTION - Gene Therapy.
USE - The pharmaceutical composition is useful for the preparation of a medicament for the treatment or prevention of a proteolysis-associated disorder in a mammal. The disorder is a disorder in which hK2 ***kallikrein*** activity is detrimental. Preferably, the disorder is a cancer, an autoimmune disorder, an inflammatory disorder, or an infectious disorder. Cancer is prostate cancer, breast cancer, or a metastasic cancer. The inflammatory disorder is Benign Prostatic Hypertrophy (all claimed). The chimeric inhibitor protein of a protease is useful for treating or preventing a proteolysis-associated disorder in a mammal.
Dwg.0/11

=> dup rem l7
PROCESSING COMPLETED FOR L7
L13 9 DUP REM L7 (11 DUPLICATES REMOVED)

=> s l13 not l10
L14 9 L13 NOT L10

=> d 1-9

L14 ANSWER 1 OF 9 MEDLINE on STN
AN 96032709 MEDLINE
DN PubMed ID: 7559414
TI Enhanced ***plasmin*** inhibition by a reactive center lysine ***mutant*** of the Kunitz-type ***protease*** ***inhibitor*** domain of the amyloid beta-protein precursor.
AU Van Nostrand W E; Schmaier A H; Siegel R S; Wagner S L; Raschke W C
CS Department of Microbiology and Molecular Genetics, College of Medicine, University of California, Irvine 92717-4025, USA.
NC HL03229 (NHLBI)
HL49566 (NHLBI)
SO Journal of biological chemistry, (1995 Sep 29) 270 (39) 22827-30.
Journal code: 2985121R. ISSN: 0021-9258.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199511
ED Entered STN: 19951227
Last Updated on STN: 19970203
Entered Medline: 19951106

L14 ANSWER 2 OF 9 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2003:77344 SCISEARCH
GA The Genuine Article (R) Number: 631QD

TI The link module from human TSG-6 inhibits neutrophil migration in a hyaluronan- and inter-alpha-inhibitor-independent manner
AU Getting S J; Mahoney D J; Cao T; Rugg M S; Fries E; Milner C M; Perretti M; Day A J (Reprint)
CS Univ Oxford, Dept Biochem, MRC, Immunochem Unit, S Parks Rd, Oxford OX1 3QU, England (Reprint); Univ Oxford, Dept Biochem, MRC, Immunochem Unit, Oxford OX1 3QU, England; St Bartholomews & Royal London Sch Med & Dent, William Harvey Res Inst, Dept Biochem Pharmacol, London EC1M 6BQ, England; Univ Uppsala, Dept Med Biochem & Microbiol, S-75123 Uppsala, Sweden
CYA England; Sweden
SO JOURNAL OF BIOLOGICAL CHEMISTRY, (27 DEC 2002) Vol. 277, No. 52, pp. 51068-51076.
Publisher: AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC, 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA.
ISSN: 0021-9258.
DT Article; Journal
LA English
REC Reference Count: 43
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L14 ANSWER 3 OF 9 LIFESCI COPYRIGHT 2004 CSA on STN
AN 2003:23443 LIFESCI
TI The Link Module from Human TSG-6 Inhibits Neutrophil Migration in a Hyaluronan- and Inter-[alpha]-inhibitor-independent Manner
AU Getting, S.J.; Mahoney, D.J.; Cao, T.; Rugg, M.S.; Fries, E.; Milner, C.M.; Perretti, M.; Day, A.J.
CS Department of Biochemical Pharmacology, The William Harvey Research Institute, St. Bartholomew's and the Royal London School of Medicine and Dentistry, London EC1M 6BQ, United Kingdom; E-mail: tony.day@bioch.ox.ac.uk.
SO Journal of Biological Chemistry [J. Biol. Chem.], vol. 277, pp. 51068-51076.
ISSN: 0021-9258.
DT Journal
FS F
LA English
SL English

L14 ANSWER 4 OF 9 BIOTECHDS COPYRIGHT 2004 THE THOMSON CORP. on STN
AN 1994-04410 BIOTECHDS
TI Protease-inhibitor-resistant serine protease enzyme engineering and expression in Escherichia coli, Saccharomyces cerevisiae, Pichia pastoris;
CHO, COS, HeLa, 293, BHK, melanoma, human hepatoma cell, NIH3T3 cell culture; application in blood-clotting related-disease therapy
PA Brit.Bio-technol.
PI WO 9403614 17 Feb 1994
AI WO 1993-GB1632 3 Aug 1993
PRAI GB 1992-16558 4 Aug 1992
DT Patent
LA English
OS WPI: 1994-065702 [08]

L14 ANSWER 5 OF 9 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:594894 HCAPLUS
DN 137:136923
TI Serpin (serine ***protease*** ***inhibitors***) ***variants*** and therapeutic uses thereof
IN Carrell, Wayne Robin; Huntington, James Andrew; Zhou, Aiwu
PA Cambridge University Technical Services Limited, UK
SO PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002060952	A1	20020808	WO 2002-GB405	20020130

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,

CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRAI GB 2001-2447 A 20010131
RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1995:438213 HCAPLUS
DN 122:178377
TI Inhibition of tumors by suppressing activity of inhibitors of proteases or nonproteolytic matrix-degrading enzymes
IN Brunner, Nils; Roemer, John; Ellis, Vincent; Pyke, Charles; Groendahl-Hansen, Jan; Pedersen, Helle; Hansen, Heine Hoei; Danoe, Keld
PA Cancerforskningsfonden af 1989, Den.
SO PCT Int. Appl., 93 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9502413	A1	19950126	WO 1994-DK288	19940718
	W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, CZ, DE, DK, FI, FI, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LV, MD, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SI, SK, SK, TJ, TT, UA, US, UZ, VN				
	RW: KE, MW, SD, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9471833	A1	19950213	AU 1994-71833	19940718
	EP 712312	A1	19960522	EP 1994-920904	19940718
	EP 712312	B1	20040407		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 10500097	T2	19980106	JP 1994-504300	19940718
	AT 263569	E	20040415	AT 1994-920904	19940718
	US 6224865	B1	20010501	US 1996-583129	19960515
	US 2001034327	A1	20011025	US 2001-836323	20010418
	US 2003096755	A1	20030522	US 2003-336513	20030102
PRAI	DK 1993-851	A	19930716		
	WO 1994-DK288	W	19940718		
	US 1996-583129	A3	19960515		
	US 2001-836323	B1	20010418		

L14 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1995:125133 HCAPLUS
DN 122:4392
TI Preparation of deletion ***mutants*** of polypeptide AN68 as ***protease*** ***inhibitors*** and use as therapeutics
IN Morishita, Hideaki; Kanamori, Toshuki; Nobuhara, Masahiro
PA Mochida Pharm Co Ltd, Japan
SO Jpn. Kokai Tokkyo Koho, 27 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 05308988	A2	19931122	JP 1992-146587	19920512
PRAI	JP 1992-146587		19920512		

L14 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1994:100559 HCAPLUS
DN 120:100559
TI Human kunitz-type ***protease*** ***inhibitor*** ***variants*** , their manufacture with recombinant cells, and their use in disease treatment
IN Bjoern, Soeren Erik; Norris, Kjeld; Norris, Fanny; Petersen, Lars Christian; Olsen, Ole Hvilsted
PA Novo Nordisk A/S, Den.
SO PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9314119	A1	19930722	WO 1993-DK2	19930107
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				

```
     AU 9333457          A1    19930803    AU 1993-33457          19930107
     AU 671611           B2    19960905
     ZA 9300098          A     19930810    ZA 1993-98             19930107
     EP 621869           A1    19941102    EP 1993-902103         19930107
     EP 621869           B1    19970423
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE
     JP 07506334         T2    19950713    JP 1993-511990         19930107
     AT 152129           E     19970515    AT 1993-902103         19930107
     FI 9403231          A     19940706    FI 1994-3231           19940706
     NO 9402552          A     19940907    NO 1994-2552           19940706
     US 5629176          A     19970513    US 1994-334773         19941104
PRAI WO 1992-DK5               19920107
     WO 1993-DK2               19930107
     US 1993-26135             19930224
OS   MARPAT 120:100559

L14  ANSWER 9 OF 9  HCAPLUS  COPYRIGHT 2004 ACS on STN
AN   1993:665385  HCAPLUS
DN   119:265385
TI     ***Variants***   of Kunitz-type   ***protease***     ***inhibitor***
     domain II of human tissue factor pathway inhibitor, their manufacture with
     recombinant cells, and their use in pharmaceuticals
IN   Norris, Fanny; Norris, Kjeld; Bjoern, Soeren Erik; Petersen, Lars
     Christian; Olsen, Ole Hvilsted
PA   Novo Nordisk A/S, Den.
SO   PCT Int. Appl., 53 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    --------------------   --------
PI   WO 9314121           A1    19930722    WO 1993-DK4            19930107
        RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
     IL 104325           A1    20001031    IL 1993-104325         19930106
     AU 9333459          A1    19930803    AU 1993-33459          19930107
     AU 676145           B2    19970306
     ZA 9300095          A     19930820    ZA 1993-95             19930107
     EP 621871           A1    19941102    EP 1993-902105         19930107
     EP 621871           B1    19970702
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE
     JP 07506335         T2    19950713    JP 1993-511992         19930107
     JP 3350549          B2    20021125
     HU 70295            A2    19950928    HU 1994-1991           19930107
     HU 218104           B     20000628
     AT 154938           E     19970715    AT 1993-902105         19930107
     ES 2104121          T3    19971001    ES 1993-902105         19930107
     PL 175422           B1    19981231    PL 1993-304468         19930107
     CZ 284911           B6    19990414    CZ 1994-1649           19930107
     FI 9403233          A     19940706    FI 1994-3233           19940706
     NO 9402550          A     19940907    NO 1994-2550           19940706
     US 5576294          A     19961119    US 1994-321658         19941012
PRAI WO 1992-DK1           A     19920107
     DK 1992-1             A     19920107
     WO 1993-DK4           A     19930107
     US 1993-21610         B1    19930222
OS   MARPAT 119:265385


=> dup rem l8
PROCESSING COMPLETED FOR L8
L15           2 DUP REM L8 (6 DUPLICATES REMOVED)

=> s l15 not l10
L16           2 L15 NOT L10

=> d 1,2

L16  ANSWER 1 OF 2     MEDLINE on STN
AN   1999432178     MEDLINE
DN   PubMed ID: 10500122
TI   Reverse biochemistry: use of macromolecular protease inhibitors to dissect
     complex biological processes and identify a membrane-type serine protease
     in epithelial cancer and normal tissue.
AU   Takeuchi T; Shuman M A; Craik C S
CS   Department of Pharmaceutical Chemistry, University of California, San
```

Francisco, CA 94143, USA.
NC CA71097 (NCI)
CA72006 (NCI)
SO Proceedings of the National Academy of Sciences of the United States of America, (1999 Sep 28) 96 (20) 11054-61.
Journal code: 7505876. ISSN: 0027-8424.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
OS GENBANK-AF133086
EM 199910
ED Entered STN: 19991101
Last Updated on STN: 20000303
Entered Medline: 19991021

L16 ANSWER 2 OF 2 BIOTECHDS COPYRIGHT 2004 THE THOMSON CORP. on STN
AN 1993-02632 BIOTECHDS
TI Use of serine protease-inhibitor C1-INH; recombinant variant production for application as hypertensive and antiinflammatory
PA Genentech
PI WO 9222320 23 Dec 1992
AI WO 1992-US4452 27 May 1992
PRAI US 1992-859781 30 Mar 1992; US 1991-716039 14 Jun 1991
DT Patent
LA English
OS WPI: 1993-017906 [02]

=> dis his

(FILE 'HOME' ENTERED AT 18:42:58 ON 08 NOV 2004)

FILE 'MEDLINE, SCISEARCH, LIFESCI, BIOTECHDS, BIOSIS, EMBASE, HCAPLUS, NTIS, ESBIOBASE, BIOTECHNO, WPIDS' ENTERED AT 18:43:10 ON 08 NOV 2004
L1 139452 S PROTEASE (5A) INHIBITOR
L2 2479 S L1 (5A) (MUTA? OR VARIANT)
L3 25 S L2 AND KALLIKREIN
L4 20 DUP REM L3 (5 DUPLICATES REMOVED)
L5 31 S L2 AND PLASMIN
L6 18 S L2 AND FACTOR XII?
L7 20 S L5 NOT L3
L8 8 S L6 NOT L3
L9 2 S L3 AND L5 AND L6
L10 2 DUP REM L9 (0 DUPLICATES REMOVED)
L11 20 S L7 NOT L10
L12 18 S L4 NOT L10
L13 9 DUP REM L7 (11 DUPLICATES REMOVED)
L14 9 S L13 NOT L10
L15 2 DUP REM L8 (6 DUPLICATES REMOVED)
L16 2 S L15 NOT L10

=> log h

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	88.10	88.31

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 18:55:15 ON 08 NOV 2004